Candel Therapeutics Showcases Glioblastoma Immunotherapy Advances at Drug Development Summit

Reuters

Feb 11

Candel <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Showcases Glioblastoma Immunotherapy Advances at Drug Development <a href="https://laohu8.com/S/SMMT">Summit</a>

Candel Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies for cancer, will participate in the 7th Annual Glioblastoma Drug Development Summit from February 17-19, 2026, in Boston, Massachusetts. Dr. Francesca Barone, Candel's Chief Scientific Officer, will present data and insights from the company's HSV-based platform and the linoserpaturev (CAN-3110) program targeting recurrent high-grade glioma. Dr. Barone will be involved in several sessions, including a workshop panel on patient stratification using omics data (Feb. 17, 8:00 a.m. ET), a conference presentation on integrating biomarkers and imaging in a Phase I/II clinical trial (Feb. 18, 9:30 a.m. ET), and a panel discussion on biomarker-based enrollment in GBM trials (Feb. 18, 12:00 p.m. ET). Links to event-related documents and materials: - PDF Version

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on February 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610540930"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610540930\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610540930?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-11 21:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610540930","market":"fut","top_or_hot":-1,"title":"Candel Therapeutics Showcases Glioblastoma Immunotherapy Advances at Drug Development Summit","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Candel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Showcases Glioblastoma Immunotherapy Advances at Drug Development <a href=\"https://laohu8.com/S/SMMT\">Summit</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Candel Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies for cancer, will participate in the 7th Annual Glioblastoma Drug Development Summit from February 17-19, 2026, in Boston, Massachusetts. Dr. Francesca Barone, Candel's Chief Scientific Officer, will present data and insights from the company's HSV-based platform and the linoserpaturev (CAN-3110) program targeting recurrent high-grade glioma. Dr. Barone will be involved in several sessions, including a workshop panel on patient stratification using omics data (Feb. 17, 8:00 a.m. ET), a conference presentation on integrating biomarkers and imaging in a Phase I/II clinical trial (Feb. 18, 9:30 a.m. ET), and a panel discussion on biomarker-based enrollment in GBM trials (Feb. 18, 12:00 p.m. ET). Links to event-related documents and materials: - PDF Version\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on February 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Candel Therapeutics Showcases Glioblastoma Immunotherapy Advances at Drug Development Summit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCandel Therapeutics Showcases Glioblastoma Immunotherapy Advances at Drug Development Summit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-11 21:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Candel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Showcases Glioblastoma Immunotherapy Advances at Drug Development <a href=\"https://laohu8.com/S/SMMT\">Summit</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Candel Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies for cancer, will participate in the 7th Annual Glioblastoma Drug Development Summit from February 17-19, 2026, in Boston, Massachusetts. Dr. Francesca Barone, Candel's Chief Scientific Officer, will present data and insights from the company's HSV-based platform and the linoserpaturev (CAN-3110) program targeting recurrent high-grade glioma. Dr. Barone will be involved in several sessions, including a workshop panel on patient stratification using omics data (Feb. 17, 8:00 a.m. ET), a conference presentation on integrating biomarkers and imaging in a Phase I/II clinical trial (Feb. 18, 9:30 a.m. ET), and a panel discussion on biomarker-based enrollment in GBM trials (Feb. 18, 12:00 p.m. ET). Links to event-related documents and materials: - PDF Version\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on February 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLc5ckyK:1","article_id":"2610540930","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610540930","pubTimestamp":1770815207,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Candel Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies for cancer, will participate in the 7th Annual Glioblastoma Drug Development Summit from February 17-19, 2026, in Boston, Massachusetts. Dr. Francesca Barone, Candel's Chief Scientific Officer, will present data and insights from the company's HSV-based platform and the linoserpaturev  program targeting recurrent high-grade glioma. Dr. Barone will be involved in several sessions, including a workshop panel on patient stratification using omics data , a conference presentation on integrating biomarkers and imaging in a Phase I/II clinical trial , and a panel discussion on biomarker-based enrollment in GBM trials . Links to event-related documents and materials: - PDF Version. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CADL":"Candel Therapeutics, Inc.","BK4539":"次新股"},"translate_title":"Candel Therapeutics在药物开发峰会上展示胶质母细胞瘤免疫疗法进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CADL":0.9},"content_text":"Candel Therapeutics Showcases Glioblastoma Immunotherapy Advances at Drug Development Summit\n\n\n        Candel Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies for cancer, will participate in the 7th Annual Glioblastoma Drug Development Summit from February 17-19, 2026, in Boston, Massachusetts. Dr. Francesca Barone, Candel's Chief Scientific Officer, will present data and insights from the company's HSV-based platform and the linoserpaturev (CAN-3110) program targeting recurrent high-grade glioma. Dr. Barone will be involved in several sessions, including a workshop panel on patient stratification using omics data (Feb. 17, 8:00 a.m. ET), a conference presentation on integrating biomarkers and imaging in a Phase I/II clinical trial (Feb. 18, 9:30 a.m. ET), and a panel discussion on biomarker-based enrollment in GBM trials (Feb. 18, 12:00 p.m. ET). Links to event-related documents and materials: - PDF Version\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on February 11, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}